Abstract
BackgroundTo test the antimicrobial potential of clove essential oil that has been less investigated on antimicrobial-resistant organisms (extended-spectrum β-lactamase-ESBL-producing Escherichia coli), we collected 135 ESBL-producing Escherichia coli strains given that E. coli is the major organism increasingly isolated as a cause of complicated urinary and gastrointestinal tract infections, which remains an important cause of therapy failure with antibiotics for the medical sector.Then, in this study, we evaluated the relationship between the antibacterial potential activity of Syzygium aromaticum essential oil (EOSA) and the expression of antibiotic-resistant genes (SHV-2, TEM-20) in plasmidic DNA on ESBL-producing E. coli using RT-PCR technique.ResultsEOSA was obtained by hydrodistillation. Using Kirby-Baüer method, we found that EOSA presented a smaller media (mean = 15.59 mm) in comparison with chloramphenicol (mean = 17.73 mm). Thus, there were significant differences (p < 0.0001). Furthermore, EOSA had an antibacterial activity, particularly on ECB132 (MIC: 10.0 mg/mL and MBC: 80.0 mg/mL), and a bacteriostatic effect by bactericidal kinetic. We found that the expression of antibiotic-resistant gene blaTEM-20 was 23.52% (4/17 strains) and no expression of blaSHV-2.EOSA presented such as majority compounds (eugenol, caryophyllene) using the GC–MS technique.ConclusionsPlant essential oils and their active ingredients have potentially high bioactivity against a different target (membranes, cytoplasm, genetic material). In this research, EOSA might become an important adjuvant against urinary and gastrointestinal diseases caused by ESBL-producing E. coli.
Highlights
To test the antimicrobial potential of clove essential oil that has been less investigated on antimi‐ crobial-resistant organisms, we collected 135 Extended-spectrum β-lactamase-producing strain (ESBL)-producing Escherichia coli strains given that E. coli is the major organism increasingly isolated as a cause of complicated urinary and gastrointestinal tract infections, which remains an important cause of therapy failure with antibiotics for the medical sector.in this study, we evaluated the relationship between the antibacterial potential activity of Syzygium aromaticum essential oil (EOSA) and the expression of antibiotic-resistant genes (SHV-2, TEM-20) in plasmidic Deoxyribonucleic acid (DNA) on extended-spectrum beta-lactamases (ESBLs)-producing E. coli using Reverse transcription polymerase chain (RT-PCR) technique
We evaluate the relationship between the antibacterial potential activity of essential oil of Syzygium aromaticum L. (EOSA) and the expression of antibiotic-resistant genes (SHV-2, TEM-20) in plasmidic DNA on ESBL-producing E. coli using RT-PCR technique
Detection of bacteria resistance genes Using plasmid DNA extraction and RT-PCR technique, we found that ESBL-E. coli strains had the expression of antibiotic-resistant gene blaTEM-20 in a 23.52% (4/17 strains) and no expression of blaSHV-2 (Table 2)
Summary
To test the antimicrobial potential of clove essential oil that has been less investigated on antimi‐ crobial-resistant organisms (extended-spectrum β-lactamase-ESBL-producing Escherichia coli), we collected 135 ESBL-producing Escherichia coli strains given that E. coli is the major organism increasingly isolated as a cause of complicated urinary and gastrointestinal tract infections, which remains an important cause of therapy failure with antibiotics for the medical sector.in this study, we evaluated the relationship between the antibacterial potential activity of Syzygium aromaticum essential oil (EOSA) and the expression of antibiotic-resistant genes (SHV-2, TEM-20) in plasmidic DNA on ESBL-producing E. coli using RT-PCR technique. The extended-spectrum beta-lactamases (ESBLs) are classified as a group of enzymes that cause resistance to the oxyiminocephalosporins (i.e., cefotaxime, ceftazidime, cefepime) and the monobactams (i.e., aztreonam). They do not produce resistance to the cephamycins (i.e., cefoxitin, cefotetan) nor to the carbapenems (i.e., imipenem, meropenem, doripenem, ertapenem) (Pitout and Laupland 2008). A higher prevalence of AROs is troublesome for the medical sector (due to complications such as chemotherapy, surgery) because infections increase patient mortality and morbidity These issues remain as an important cause of therapy failure with antibiotics and have serious infection-control-related consequences according to the World Health Organization (WHO) (Seale et al 2017)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
